ISTITUTO ONCOLOGICO VENETO
🇮🇹Italy
Silibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type, Newly Diagnosed Glioblastoma Patients
Not Applicable
Not yet recruiting
- Conditions
- GlioblastomaIDH Wild-type and STAT3-positive Glioblastoma
- First Posted Date
- 2025-05-09
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Istituto Oncologico Veneto IRCCS
- Target Recruit Count
- 110
- Registration Number
- NCT06964815
- Locations
- 🇮🇹
Istituto Oncologico Veneto, Padova, Italy/Padova, Italy
Assessing Financial Toxicity Using the PROFFIT Questionnaire in Patients Treated With Mini-invasive Approach for Urological Malignancies.
Not yet recruiting
- Conditions
- Prostate CancerBladder CancerKidney Cancer
- First Posted Date
- 2025-05-02
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Istituto Oncologico Veneto IRCCS
- Target Recruit Count
- 120
- Registration Number
- NCT06955910
- Locations
- 🇮🇹
Istituto Oncologico Veneto, Padova, Italy/Padova, Italy
Preventive Application of Single-use Negative Pressure Wound Therapy (sNPWT) in the Postoperative Course of Radiotreatated Limb Sarcoma Surgery
Not Applicable
Not yet recruiting
- Conditions
- SarcomaSarcoma,Soft Tissue
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Istituto Oncologico Veneto IRCCS
- Target Recruit Count
- 48
- Registration Number
- NCT06941194
- Locations
- 🇮🇹
Istituto Oncologico Veneto, Padova, Italy/Padova, Italy
Scarless Advanced Breast Extended Oncoplasty: The ScarABEO Study
Recruiting
- Conditions
- Breast CancerOncoplastic Breast SurgeryChest Wall Perforator FlapOncoplastic Breast-conserving Surgery
- First Posted Date
- 2025-04-02
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Istituto Oncologico Veneto IRCCS
- Target Recruit Count
- 250
- Registration Number
- NCT06906237
- Locations
- 🇮🇹
Veneto Institute of Oncology, Padova, Italy
Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype
Not Applicable
Not yet recruiting
- Conditions
- Primary Visceral Tumors of Any HistotypeVisceral LesionsLiver CancerLiver Metastasis Colon CancerMelanomaPrimary Pancreatic TumorRetroperitoneal SarcomaAbdominal and/or Peritoneal LocalizationsMerkel Cell CarcinomaSquamous Cell Carcinoma
- First Posted Date
- 2024-12-31
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Istituto Oncologico Veneto IRCCS
- Target Recruit Count
- 24
- Registration Number
- NCT06753136
- Locations
- 🇮🇹
Istituto Oncologico Veneto, Padova, Italy
GISEL:Registry of Breast Cancer Patients Treated With ECT
Completed
- Conditions
- Breast CancerBreast Cancer RecurrentBreast Cancer Metastatic
- Interventions
- Device: Electrochemotherapy (ECT)
- First Posted Date
- 2024-11-11
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Istituto Oncologico Veneto IRCCS
- Target Recruit Count
- 205
- Registration Number
- NCT06683404
- Locations
- 🇮🇹
Veneto Institute of Oncology IRCCS, Padova, Italy
Novel Therapeutic Approach for Human T-cell Malignancies
Recruiting
- Conditions
- T-Cell Leukemia/Lymphoma, Adult
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Istituto Oncologico Veneto IRCCS
- Target Recruit Count
- 120
- Registration Number
- NCT06600568
- Locations
- 🇮🇹
Istituto Nazionale Tumori Fondazione G.Pascale, Napoli, Italy
🇮🇹Istituto Oncologico Veneto, Padova, Italy
Next Generation Sequencing Method for the Detection of EGFR Gene Mutations in the Plasma of Patients with Lung Cancer
Not Applicable
Recruiting
- Conditions
- Carcinoma, Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Diagnostic Test: Plasma- SeqSensei™ Solid Cancer IVD Kit (Sysmex)Diagnostic Test: cobas® EGFR Mutation Test v2 (Roche)
- First Posted Date
- 2024-09-13
- Last Posted Date
- 2024-09-13
- Lead Sponsor
- Istituto Oncologico Veneto IRCCS
- Target Recruit Count
- 118
- Registration Number
- NCT06595498
- Locations
- 🇮🇹
Istituto Oncologico Veneto, Padova, Italy
Immune Microenvironment and Gene Expression Profiling in Mesothelioma
Recruiting
- Conditions
- MesotheliomaMesotheliomas PleuralMesothelioma; Lung
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Istituto Oncologico Veneto IRCCS
- Target Recruit Count
- 220
- Registration Number
- NCT06581549
- Locations
- 🇮🇹
Istituto Clinico Humanitas, Rozzano, Milano, Italy
🇮🇹Centro di Riferimento Oncologico (CRO) IRCCS, Aviano, Pordenone, Italy
🇮🇹Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
Regorafenib for Recurrent Grade 2 and 3 Meningioma (MIRAGE Trial)
Phase 2
Recruiting
- Conditions
- Meningioma, Malignant
- Interventions
- Drug: Local Standard of Care
- First Posted Date
- 2024-02-23
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Istituto Oncologico Veneto IRCCS
- Target Recruit Count
- 104
- Registration Number
- NCT06275919
- Locations
- 🇮🇹
Policlinico San Martino, Genova, Italy
🇮🇹Spedali Riuniti, Livorno, Italy
🇮🇹Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy
© Copyright 2025. All Rights Reserved by MedPath